secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001140361-23-042067
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.03, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences stockholders approve key proposals for business combination; outside date extended to Oct 30
--------------------------------------------------------------------------------

- Stockholders approved issuance of shares (10.5M for), conversion of preferred stock, increase authorized shares to 400M, and reverse split 1:10–1:60.
- Proposals to create non-voting common stock and allow stockholder action by written consent did not pass.
- Business combination outside date extended to October 30, 2023 via Second Amendment to Business Combination Agreement.
- Company has not yet received required CSRC approval; no assurance transaction will close by outside date.
- Certificate of Elimination filed for Series Y Preferred Stock, removing all designations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/0001140361-23-042067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123042067/brhc20058284_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-042067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer